ABSTRACT
Diagnosing childhood pulmonary tuberculosis (TB) is a challenge, and this led the Uganda National Tuberculosis and Leprosy Program (NTLP) to develop a clinical treatment decision algorithm (TDA) for children. However, there is limited data on its accuracy and how it compares to new World Health Organization (WHO) TB TDAs for children. This study aimed to evaluate and compare the accuracy of the 2017 Uganda NTLP algorithm with the 2022 WHO TDAs for TB among children in Kampala, Uganda.
We retrospectively assessed children <15 years old who underwent an evaluation for TB between November 2018 and November 2022. Children were classified as per National Institutes of Health (NIH) consensus definitions. We applied the 2017 Uganda NTLP and 2022 WHO algorithms (A with chest x-ray [CXR], B without CXR) to make a decision to treat for TB or not, and calculated accuracy in reference to Confirmed vs. Unlikely TB, as well as a microbiological and composite reference standard. We compared accuracy of the Uganda NTLP algorithm to the WHO TDAs among children <10 years old.
A total of 699 children were included in this analysis with 64% (451/699) under 5 years, 53% (373/669) were male, 12% (85/699) were Xpert Ultra positive, 11% (74/669) were HIV positive and 6% had severe acute malnutrition (SAM). The Uganda NTLP algorithm had a sensitivity of 97.9% (95% CI: 96.4-99.4) and specificity of 25.9% (95% CI: 21.2-30.7). If CXR was considered unavailable, sensitivity was 97.9% (95% CI: 96.4-99.4) and specificity 28.1% (95% CI: 23.2-33.0). Accuracy remained similar among high-risk children. In comparison, WHO TDAs had similar sensitivity to the Uganda NTLP, but algorithm A was more specific (32.2%, 95% CI: 26.9-37.5) and algorithm B was less specific (15.4%, 95% CI: 11.3-19.5).
Both the Uganda NTLP and WHO TDAs had high sensitivity but low specificity. The WHO TDAs had better specificity than the NTLP algorithm with CXR, and worse specificity without CXR. Further optimization of the algorithms is needed to improve specificity and reduce over-treatment of TB in children.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the National Institutes of Health (R01HL139717 and U01AI152087 to AC, and R01HL169449 and K23HL153581 to DJ).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Makerere University School of Medicine Research and Ethics Committee as well as the Mulago Hospital Research and Ethics Committee, Kampala, Uganda (IRB number 12884), and the institutional review board at the University of California, San Francisco (UCSF), United States of America
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵** Co-senior authors;
Data Availability
Data set uploaded as supplementary material
